

National Board of Examinations

Question Paper Name :	DrNB CLINICAL HAEMATOLOGY Paper3
Subject Name :	DrNB CLINICAL HAEMATOLOGY Paper3
Creation Date :	2022-12-26 13:13:00
Duration :	180
Share Answer Key With Delivery Engine :	No
Actual Answer Key :	No

DrNB CLINICAL HAEMATOLOGY Paper3

Group Number :	1
Group Id :	3271871896
Group Maximum Duration :	0
Group Minimum Duration :	180
Show Attended Group? :	No
Edit Attended Group? :	No
Group Marks :	100
Is this Group for Examiner? :	No
Examiner permission :	Cant View
Show Progress Bar? :	No

DrNB CLINICAL HAEMATOLOGY Paper3

Section Id :	3271871899
Section Number :	1
Section type :	Offline

Mandatory or Optional : Mandatory

Number of Questions to be attempted : 10

Section Marks : 100

Enable Mark as Answered Mark for Review and Clear Response : Yes

Maximum Instruction Time : 0

Sub-Section Number : 1

Sub-Section Id : 3271871903

Question Shuffling Allowed : No

Is Section Default? : null

Question Number : 1 Question Id : 32718718572 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

Please write your answers in the answer booklet within the allotted pages as follows:-

Question Number	Answer to be attempted within	Question Number	Answer to be attempted within
Q. 1	Page 1-5	Q. 6	Page 26-30
Q. 2	Page 6-10	Q. 7	Page 31-35
Q. 3	Page 11-15	Q. 8	Page 36-40
Q. 4	Page 16-20	Q. 9	Page 41-45
Q. 5	Page 21-25	Q. 10	Page 46-50

1. A 68-year-old male was found to have ataxia with ECOG – 3 performance status and evaluation revealed an ICSOL in the posterior fossa. A biopsy from the ICSOL was suggestive of high-grade DLBCL. His HIV status was negative. His PET/CT revealed no FDG avidity in any other body part other than the ICSOL:

- Suggest what other investigations are recommended for identifying the extent of the disease and confirming the diagnosis? [3]
- Discuss the other possible clinical manifestations of this disease. [2]
- Discuss the management of this patient. [5]

Question Number : 2 Question Id : 32718718573 Question Type : SUBJECTIVE Consider As

Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

A 21-year-old lady presented with thrombocytopenia, renal failure and fragmented RBCs on the peripheral blood smear:

- a) What are the differential diagnoses for this patient? [5]
- b) Give an algorithmic approach for managing this patient. [5]

Question Number : 3 Question Id : 32718718574 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

You, as a young hematologist, have been tasked to train the newly inducted nurses to the BMT unit. Kindly enumerate the important points that you would emphasize in Nursing care under the following headings:

- a) Central Venous Access Device (CVAD) care. [4]
- b) Nutrition in transplant patients. [3]
- c) Care of the transplant patient in the Neutropenic phase. [3]

Question Number : 4 Question Id : 32718718575 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

You have been contacted by a family friend diagnosed with Relapse Refractory Multiple Myeloma (RRMM) about the newer anti-BCMA therapies. Please write the mechanism of action (MOA), benefits, and adverse events of each of these drugs:

- a) Anti-BCMA CAR-T therapy. [4]
- b) Belantamab mafodotin. [3]
- c) Teclistamab. [3]

Question Number : 5 Question Id : 32718718576 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction

Time : 0

Correct Marks : 10

Antifungals are a very important component of the Hematologist's prescription. Please discuss the following regarding the antifungals:

- a) Diagrammatic representation of the mechanism of action (MOA) of all the classes of antifungals. [2]
- b) Role of antifungal prophylaxis (both primary and secondary) in hematological diseases. [4]
- c) Antifungals in febrile neutropenic patients. [4]

Question Number : 6 Question Id : 32718718577 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

The recent advent and usage of BCL-2 inhibitors have changed the disease spectrum of many hematological diseases. Discuss the BCL-2 inhibitors under the following headings substantiated by clinical trial data:

- a) Role in AML. [4]
- b) Role in CLL. [4]
- c) Role in Multiple Myeloma. [2]

Question Number : 7 Question Id : 32718718578 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

Discuss the following regarding Double hit lymphoma:

- a) Current concepts. [5]
- b) Controversies in the diagnosis/ management. [5]

Question Number : 8 Question Id : 32718718579 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

A 32-year-old male was found to have Myelofibrosis on Bone Marrow examination when evaluated for pancytopenia:

- a) How will you assess his prognosis? [4]
- b) Enumerate the symptoms-directed therapy in a young male with myelofibrosis. [3]
- c) Describe the role of Ruxolitinib in this patient. [3]

Question Number : 9 Question Id : 32718718580 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

Discuss the steps you would undertake for the quality control in a coagulation lab under the following headings:

- a) Pre-analytic errors. [5]
- b) Analytic errors. [5]

Question Number : 10 Question Id : 32718718581 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

Recently FDA has approved the costliest therapy for any disease in the World, i.e., Gene therapy for Hemophilia B, at a whopping cost of 23 crores per vial:

- a) Enumerate the principles of gene therapy. [4]
- b) Enumerate the type of vectors specifically related to the:
 - i) Characteristics of the Vector backbone. [2]
 - ii) Integrating Vs. Non-integrating vectors. [2]
 - iii) Strategies to reduce immunogenicity. [2]